Clinical and technical considerations for mediastinal Hodgkin lymphoma protontherapy based on a single-center early experience
- 1 December 2021
- journal article
- research article
- Published by Elsevier in Cancer/Radiothérapie
- Vol. 25 (8) , 779-785
Abstract
No abstract availableKeywords
This publication has 25 references indexed in Scilit:
- Late Cardiac Toxicity After Mediastinal Radiation Therapy for Hodgkin Lymphoma: Contributions of Coronary Artery and Whole Heart Dose-Volume Variables to Risk PredictionInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2017
- Early Positron Emission Tomography Response–Adapted Treatment in Stage I and II Hodgkin Lymphoma: Final Results of the Randomized EORTC/LYSA/FIL H10 TrialJournal of Clinical Oncology, 2017
- Long-term risk of second malignancy and cardiovascular disease after Hodgkin lymphoma treatmentHematology-American Society Hematology Education Program, 2016
- Whole breast proton irradiation for maximal reduction of heart dose in breast cancer patientsBreast Cancer Research and Treatment, 2014
- Involved-Node Proton Therapy in Combined Modality Therapy for Hodgkin Lymphoma: Results of a Phase 2 StudyInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2014
- Selection of patients for radiotherapy with protons aiming at reduction of side effects: The model-based approachRadiotherapy and Oncology, 2013
- Volumetric modulated arc therapy: a review of current literature and clinical use in practiceBritish Journal of Radiology, 2011
- Applications of new irradiation modalities in patients with lymphoma: Promises and uncertaintiesWorld Journal of Radiology, 2011
- Should Randomized Clinical Trials Be Required for Proton Radiotherapy?Journal of Clinical Oncology, 2008
- Late cardiotoxicity after treatment for Hodgkin lymphomaBlood, 2006